Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics
Atherosclerosis, one of the life-threatening cardiovascular diseases (CVDs), has been
demonstrated to be a chronic inflammatory disease, and inflammatory and immune …
demonstrated to be a chronic inflammatory disease, and inflammatory and immune …
[HTML][HTML] PCSK9 biology and its role in atherothrombosis
It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …
[HTML][HTML] PCSK9 inhibition: from current advances to evolving future
C Liu, J Chen, H Chen, T Zhang, D He, Q Luo, J Chi… - Cells, 2022 - mdpi.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
PCSK9: from basic science discoveries to clinical trials
Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now
common parlance among scientists and clinicians interested in prevention and treatment of …
common parlance among scientists and clinicians interested in prevention and treatment of …
The evolving future of PCSK9 inhibitors
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …
PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
PCSK9 degrades low-density lipoprotein cholesterol (LDL) receptors and subsequently
increases serum LDL cholesterol. Clinical trials show that inhibition of PCSK9 efficiently …
increases serum LDL cholesterol. Clinical trials show that inhibition of PCSK9 efficiently …
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
ZH Tang, J Peng, Z Ren, J Yang, TT Li, TH Li, Z Wang… - Atherosclerosis, 2017 - Elsevier
Background and aims Proprotein convertase subtilisin/kexin 9 (PCSK9) has emerged as a
popular target in the development of new cholesterol-lowering drugs and therapeutic …
popular target in the development of new cholesterol-lowering drugs and therapeutic …
[HTML][HTML] Small rodent models of atherosclerosis
Y Zhao, H Qu, Y Wang, W **
atherosclerosis make rodents ideal for atherosclerosis research. However, none of the …
atherosclerosis make rodents ideal for atherosclerosis research. However, none of the …
Liver fat accumulation is associated with circulating PCSK9
Background: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular
disease independently of classic risk factors. Proprotein Convertase Subtilisin/Kexin type 9 …
disease independently of classic risk factors. Proprotein Convertase Subtilisin/Kexin type 9 …
An update on the role of PCSK9 in atherosclerosis
910 levels, whereas PCSK9 overexpression did not cause an increase in plasma lipids but
in atherosclerotic lesion size18, 19). The Atheroma IVUS study revealed that the necrotic …
in atherosclerotic lesion size18, 19). The Atheroma IVUS study revealed that the necrotic …